HIV / AIDS - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 886 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

HIV / AIDS - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'HIV / AIDS - Pipeline Review, H1 2016', provides an overview of the HIV / AIDS pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for HIV / AIDS, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for HIV / AIDS and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of HIV / AIDS
- The report reviews pipeline therapeutics for HIV / AIDS by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved HIV / AIDS therapeutics and enlists all their major and minor projects
- The report assesses HIV / AIDS therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for HIV / AIDS

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for HIV / AIDS
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding HIV / AIDS pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
Introduction 9
HIV / AIDS Overview 10
Therapeutics Development 11
HIV / AIDS - Therapeutics under Development by Companies 13
HIV / AIDS - Therapeutics under Investigation by Universities/Institutes 25
HIV / AIDS - Pipeline Products Glance 31
HIV / AIDS - Products under Development by Companies 35
HIV / AIDS - Products under Investigation by Universities/Institutes 53
HIV / AIDS - Companies Involved in Therapeutics Development 62
HIV / AIDS - Therapeutics Assessment 194
Drug Profiles 211
HIV / AIDS - Dormant Projects 779
HIV / AIDS - Discontinued Products 824
HIV / AIDS - Product Development Milestones 831
Appendix 843

List of Tables

Number of Products under Development for HIV / AIDS, H1 2016 53
Number of Products under Development for HIV / AIDS - Comparative Analysis, H1 2016 54
Number of Products under Development by Companies, H1 2016 56
Number of Products under Development by Companies, H1 2016 (Contd..1) 57
Number of Products under Development by Companies, H1 2016 (Contd..2) 58
Number of Products under Development by Companies, H1 2016 (Contd..3) 59
Number of Products under Development by Companies, H1 2016 (Contd..4) 60
Number of Products under Development by Companies, H1 2016 (Contd..5) 61
Number of Products under Development by Companies, H1 2016 (Contd..6) 62
Number of Products under Development by Companies, H1 2016 (Contd..7) 63
Number of Products under Development by Companies, H1 2016 (Contd..8) 64
Number of Products under Development by Companies, H1 2016 (Contd..9) 65
Number of Products under Development by Companies, H1 2016 (Contd..10) 66
Number of Products under Investigation by Universities/Institutes, H1 2016 67
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 68
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 69
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 70
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..4) 71
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..5) 72
Comparative Analysis by Late Stage Development, H1 2016 73
Comparative Analysis by Clinical Stage Development, H1 2016 74
Comparative Analysis by Early Stage Development, H1 2016 75
Comparative Analysis by Unknown Stage Development, H1 2016 76
Products under Development by Companies, H1 2016 77
Products under Development by Companies, H1 2016 (Contd..1) 78
Products under Development by Companies, H1 2016 (Contd..2) 79
Products under Development by Companies, H1 2016 (Contd..3) 80
Products under Development by Companies, H1 2016 (Contd..4) 81
Products under Development by Companies, H1 2016 (Contd..5) 82
Products under Development by Companies, H1 2016 (Contd..6) 83
Products under Development by Companies, H1 2016 (Contd..7) 84
Products under Development by Companies, H1 2016 (Contd..8) 85
Products under Development by Companies, H1 2016 (Contd..9) 86
Products under Development by Companies, H1 2016 (Contd..10) 87
Products under Development by Companies, H1 2016 (Contd..11) 88
Products under Development by Companies, H1 2016 (Contd..12) 89
Products under Development by Companies, H1 2016 (Contd..13) 90
Products under Development by Companies, H1 2016 (Contd..14) 91
Products under Development by Companies, H1 2016 (Contd..15) 92
Products under Development by Companies, H1 2016 (Contd..16) 93
Products under Development by Companies, H1 2016 (Contd..17) 94
Products under Investigation by Universities/Institutes, H1 2016 95
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 96
Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 97
Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 98
Products under Investigation by Universities/Institutes, H1 2016 (Contd..4) 99
Products under Investigation by Universities/Institutes, H1 2016 (Contd..5) 100
Products under Investigation by Universities/Institutes, H1 2016 (Contd..6) 101
Products under Investigation by Universities/Institutes, H1 2016 (Contd..7) 102
Products under Investigation by Universities/Institutes, H1 2016 (Contd..8) 103
HIV / AIDS - Pipeline by Abivax S.A., H1 2016 104
HIV / AIDS - Pipeline by AdAlta Pty Ltd., H1 2016 105
HIV / AIDS - Pipeline by Advanced Genetic Systems, Inc., H1 2016 106
HIV / AIDS - Pipeline by Akshaya Bio Inc., H1 2016 107
HIV / AIDS - Pipeline by AlbaJuna Therapeutics, H1 2016 108
HIV / AIDS - Pipeline by Altor BioScience Corporation, H1 2016 109
HIV / AIDS - Pipeline by Altravax, Inc., H1 2016 110
HIV / AIDS - Pipeline by Amarna Therapeutics B.V., H1 2016 111
HIV / AIDS - Pipeline by American Gene Technologies International Inc., H1 2016 112
HIV / AIDS - Pipeline by Amplyx Pharmaceuticals, Inc., H1 2016 113
HIV / AIDS - Pipeline by Amunix Operating Inc. , H1 2016 114
HIV / AIDS - Pipeline by Antigen Express, Inc., H1 2016 115
HIV / AIDS - Pipeline by Aphios Corporation, H1 2016 116
HIV / AIDS - Pipeline by Apotex Inc., H1 2016 117
HIV / AIDS - Pipeline by Argos Therapeutics, Inc., H1 2016 118
HIV / AIDS - Pipeline by Arno Therapeutics, Inc., H1 2016 119
HIV / AIDS - Pipeline by Avexa Limited, H1 2016 120
HIV / AIDS - Pipeline by BCI Pharma, H1 2016 121
HIV / AIDS - Pipeline by BioClonetics Immunotherapeutics, Inc., H1 2016 122
HIV / AIDS - Pipeline by Bionor Pharma ASA, H1 2016 123
HIV / AIDS - Pipeline by Biosantech SA, H1 2016 124
HIV / AIDS - Pipeline by Biotron Limited, H1 2016 125
HIV / AIDS - Pipeline by Boehringer Ingelheim GmbH, H1 2016 126
HIV / AIDS - Pipeline by C4X Discovery Holdings PLC, H1 2016 127
HIV / AIDS - Pipeline by CEL-SCI Corporation, H1 2016 128
HIV / AIDS - Pipeline by Celgene Corporation, H1 2016 129
HIV / AIDS - Pipeline by Celldex Therapeutics, Inc., H1 2016 130
HIV / AIDS - Pipeline by Chipscreen Biosciences Ltd, H1 2016 131
HIV / AIDS - Pipeline by CompleGen, Inc., H1 2016 132
HIV / AIDS - Pipeline by ContraVir Pharmaceuticals, Inc., H1 2016 133
HIV / AIDS - Pipeline by Critical Outcome Technologies Inc., H1 2016 134
HIV / AIDS - Pipeline by CureVac GmbH, H1 2016 135
HIV / AIDS - Pipeline by Cytodyn Inc., H1 2016 136
HIV / AIDS - Pipeline by Enzo Biochem, Inc., H1 2016 137
HIV / AIDS - Pipeline by EpiVax, Inc., H1 2016 138
HIV / AIDS - Pipeline by eTheRNA Immunotherapies NV, H1 2016 139
HIV / AIDS - Pipeline by Etubics Corporation, H1 2016 140
HIV / AIDS - Pipeline by Evofem, Inc., H1 2016 141
HIV / AIDS - Pipeline by FIT Biotech Oy, H1 2016 142
HIV / AIDS - Pipeline by Formune S.L., H1 2016 143
HIV / AIDS - Pipeline by Fountain Biopharma Inc., H1 2016 144
HIV / AIDS - Pipeline by Frontier Biotechnologies Co., Ltd, H1 2016 145
HIV / AIDS - Pipeline by GeneCure LLC, H1 2016 146
HIV / AIDS - Pipeline by Genetic Immunity, Inc, H1 2016 147
HIV / AIDS - Pipeline by Genticel S.A., H1 2016 148
HIV / AIDS - Pipeline by GeoVax Labs, Inc., H1 2016 149
HIV / AIDS - Pipeline by Gilead Sciences, Inc., H1 2016 150
HIV / AIDS - Pipeline by GlaxoSmithKline Plc, H1 2016 151
HIV / AIDS - Pipeline by Globeimmune, Inc., H1 2016 152
HIV / AIDS - Pipeline by H-Phar S.A., H1 2016 153
HIV / AIDS - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2016 154
HIV / AIDS - Pipeline by Heat Biologics, Inc., H1 2016 155
HIV / AIDS - Pipeline by iCo Therapeutics Inc., H1 2016 156
HIV / AIDS - Pipeline by ID Pharma Co., Ltd., H1 2016 157
HIV / AIDS - Pipeline by Immune Response BioPharma, Inc., H1 2016 158
HIV / AIDS - Pipeline by Immunocore Limited, H1 2016 159
HIV / AIDS - Pipeline by ImQuest Life Sciences, H1 2016 160
HIV / AIDS - Pipeline by InnaVirVax SA, H1 2016 161
HIV / AIDS - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 162
HIV / AIDS - Pipeline by Japan Tobacco Inc., H1 2016 163
HIV / AIDS - Pipeline by Johnson & Johnson, H1 2016 164
HIV / AIDS - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 165
HIV / AIDS - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2016 166
HIV / AIDS - Pipeline by Longevity Biotech, Inc, H1 2016 167
HIV / AIDS - Pipeline by MacroGenics, Inc., H1 2016 168
HIV / AIDS - Pipeline by Medestea Research & Production S.p.A., H1 2016 169
HIV / AIDS - Pipeline by Medivir AB, H1 2016 170
HIV / AIDS - Pipeline by Merck & Co., Inc., H1 2016 171
HIV / AIDS - Pipeline by Mologen AG, H1 2016 172
HIV / AIDS - Pipeline by Mymetics Corporation, H1 2016 173
HIV / AIDS - Pipeline by Myrexis, Inc., H1 2016 174
HIV / AIDS - Pipeline by NanoBio Corporation, H1 2016 175
HIV / AIDS - Pipeline by NanoViricides, Inc., H1 2016 176
HIV / AIDS - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016 177
HIV / AIDS - Pipeline by NeED Pharma s.r.l., H1 2016 178
HIV / AIDS - Pipeline by New World Laboratories, Inc., H1 2016 179
HIV / AIDS - Pipeline by Novartis AG, H1 2016 180
HIV / AIDS - Pipeline by Omeros Corporation, H1 2016 181
HIV / AIDS - Pipeline by Oncolys BioPharma Inc., H1 2016 182
HIV / AIDS - Pipeline by OncoNOx ApS, H1 2016 183
HIV / AIDS - Pipeline by Oncovir, Inc., H1 2016 184
HIV / AIDS - Pipeline by Orbis Biosciences, Inc., H1 2016 185
HIV / AIDS - Pipeline by Osel, Inc., H1 2016 186
HIV / AIDS - Pipeline by OyaGen Inc., H1 2016 187
HIV / AIDS - Pipeline by PaxVax, Inc., H1 2016 188
HIV / AIDS - Pipeline by Pepscan Therapeutics, H1 2016 189
HIV / AIDS - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2016 190
HIV / AIDS - Pipeline by Pfizer Inc., H1 2016 191
HIV / AIDS - Pipeline by Pharis Biotec GmbH, H1 2016 192
HIV / AIDS - Pipeline by Pharmsynthez, H1 2016 193
HIV / AIDS - Pipeline by Phoenix Biotechnology, Inc., H1 2016 194
HIV / AIDS - Pipeline by Polymun Scientific Immunbiologische Forschung GmbH, H1 2016 195
HIV / AIDS - Pipeline by Presidio Pharmaceuticals, Inc., H1 2016 196
HIV / AIDS - Pipeline by Profectus BioSciences, Inc., H1 2016 197
HIV / AIDS - Pipeline by ReceptoPharm, Inc., H1 2016 198
HIV / AIDS - Pipeline by Rodos BioTarget GmbH, H1 2016 199
HIV / AIDS - Pipeline by Sangamo BioSciences, Inc., H1 2016 200
HIV / AIDS - Pipeline by Sanofi, H1 2016 201
HIV / AIDS - Pipeline by Sanofi Pasteur SA, H1 2016 202
HIV / AIDS - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016 203
HIV / AIDS - Pipeline by SEEK Group, H1 2016 204
HIV / AIDS - Pipeline by Serometrix, LLC, H1 2016 205
HIV / AIDS - Pipeline by Sirenas Marine Discovery LLC, H1 2016 206
HIV / AIDS - Pipeline by Spider Biotech, H1 2016 207
HIV / AIDS - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016 208
HIV / AIDS - Pipeline by Staidson (Beijing) Biopharmaceuticals Co., Ltd., H1 2016 209
HIV / AIDS - Pipeline by Starpharma Holdings Limited, H1 2016 210
HIV / AIDS - Pipeline by Susavion Biosciences, Inc., H1 2016 211
HIV / AIDS - Pipeline by Taiga Biotechnologies, Inc., H1 2016 212
HIV / AIDS - Pipeline by TaiMed Biologics Inc., H1 2016 213
HIV / AIDS - Pipeline by Takara Bio Inc., H1 2016 214
HIV / AIDS - Pipeline by TechnoVax, Inc., H1 2016 215
HIV / AIDS - Pipeline by TeneoBio Inc, H1 2016 216
HIV / AIDS - Pipeline by TetraLogic Pharmaceuticals, H1 2016 217
HIV / AIDS - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 218
HIV / AIDS - Pipeline by TGV-Laboratories, H1 2016 219
HIV / AIDS - Pipeline by Theraclone Sciences, Inc., H1 2016 220
HIV / AIDS - Pipeline by Theravectys SA, H1 2016 221
HIV / AIDS - Pipeline by Tobira Therapeutics, Inc., H1 2016 222
HIV / AIDS - Pipeline by Tomegavax, Inc., H1 2016 223
HIV / AIDS - Pipeline by Transgene Biotek Limited, H1 2016 224
HIV / AIDS - Pipeline by TVAX Biomedical, Inc., H1 2016 225
HIV / AIDS - Pipeline by United Biomedical, Inc., H1 2016 226
HIV / AIDS - Pipeline by United Therapeutics Corporation, H1 2016 227
HIV / AIDS - Pipeline by Vaccibody AS, H1 2016 228
HIV / AIDS - Pipeline by Vault Pharma Inc., H1 2016 229
HIV / AIDS - Pipeline by VDA Pharma, Inc., H1 2016 230
HIV / AIDS - Pipeline by VG Life Sciences, Inc., H1 2016 231
HIV / AIDS - Pipeline by Vichem Chemie Research Ltd., H1 2016 232
HIV / AIDS - Pipeline by ViiV Healthcare Limited, H1 2016 233
HIV / AIDS - Pipeline by Viriom Ltd., H1 2016 234
HIV / AIDS - Pipeline by ViroStatics srl, H1 2016 235
Assessment by Monotherapy Products, H1 2016 236
Assessment by Combination Products, H1 2016 237
Number of Products by Stage and Target, H1 2016 239
Number of Products by Stage and Mechanism of Action, H1 2016 244
Number of Products by Stage and Route of Administration, H1 2016 250
Number of Products by Stage and Molecule Type, H1 2016 252
HIV / AIDS - Dormant Projects, H1 2016 821
HIV / AIDS - Dormant Projects (Contd..1), H1 2016 822
HIV / AIDS - Dormant Projects (Contd..2), H1 2016 823
HIV / AIDS - Dormant Projects (Contd..3), H1 2016 824
HIV / AIDS - Dormant Projects (Contd..4), H1 2016 825
HIV / AIDS - Dormant Projects (Contd..5), H1 2016 826
HIV / AIDS - Dormant Projects (Contd..6), H1 2016 827
HIV / AIDS - Dormant Projects (Contd..7), H1 2016 828
HIV / AIDS - Dormant Projects (Contd..8), H1 2016 829
HIV / AIDS - Dormant Projects (Contd..9), H1 2016 830
HIV / AIDS - Dormant Projects (Contd..10), H1 2016 831
HIV / AIDS - Dormant Projects (Contd..11), H1 2016 832
HIV / AIDS - Dormant Projects (Contd..12), H1 2016 833
HIV / AIDS - Dormant Projects (Contd..13), H1 2016 834
HIV / AIDS - Dormant Projects (Contd..14), H1 2016 835
HIV / AIDS - Dormant Projects (Contd..15), H1 2016 836
HIV / AIDS - Dormant Projects (Contd..16), H1 2016 837
HIV / AIDS - Dormant Projects (Contd..17), H1 2016 838
HIV / AIDS - Dormant Projects (Contd..18), H1 2016 839
HIV / AIDS - Dormant Projects (Contd..19), H1 2016 840
HIV / AIDS - Dormant Projects (Contd..20), H1 2016 841
HIV / AIDS - Dormant Projects (Contd..21), H1 2016 842
HIV / AIDS - Dormant Projects (Contd..22), H1 2016 843
HIV / AIDS - Dormant Projects (Contd..23), H1 2016 844
HIV / AIDS - Dormant Projects (Contd..24), H1 2016 845
HIV / AIDS - Dormant Projects (Contd..25), H1 2016 846
HIV / AIDS - Dormant Projects (Contd..26), H1 2016 847
HIV / AIDS - Dormant Projects (Contd..27), H1 2016 848
HIV / AIDS - Dormant Projects (Contd..28), H1 2016 849
HIV / AIDS - Dormant Projects (Contd..29), H1 2016 850
HIV / AIDS - Dormant Projects (Contd..30), H1 2016 851
HIV / AIDS - Dormant Projects (Contd..31), H1 2016 852
HIV / AIDS - Dormant Projects (Contd..32), H1 2016 853
HIV / AIDS - Dormant Projects (Contd..33), H1 2016 854
HIV / AIDS - Dormant Projects (Contd..34), H1 2016 855
HIV / AIDS - Dormant Projects (Contd..35), H1 2016 856
HIV / AIDS - Dormant Projects (Contd..36), H1 2016 857
HIV / AIDS - Dormant Projects (Contd..37), H1 2016 858
HIV / AIDS - Dormant Projects (Contd..38), H1 2016 859
HIV / AIDS - Dormant Projects (Contd..39), H1 2016 860
HIV / AIDS - Dormant Projects (Contd..40), H1 2016 861
HIV / AIDS - Dormant Projects (Contd..41), H1 2016 862
HIV / AIDS - Dormant Projects (Contd..42), H1 2016 863
HIV / AIDS - Dormant Projects (Contd..43), H1 2016 864
HIV / AIDS - Dormant Projects (Contd..44), H1 2016 865
HIV / AIDS - Discontinued Products, H1 2016 866
HIV / AIDS - Discontinued Products (Contd..1), H1 2016 867
HIV / AIDS - Discontinued Products (Contd..2), H1 2016 868
HIV / AIDS - Discontinued Products (Contd..3), H1 2016 869
HIV / AIDS - Discontinued Products (Contd..4), H1 2016 870
HIV / AIDS - Discontinued Products (Contd..5), H1 2016 871
HIV / AIDS - Discontinued Products (Contd..6), H1 2016 872